24
total announcements
VIYASH.NS · 15 min delayed
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about the allotment of 6,12,773 equity shares under the Sequent Scientific Limited Employee Stock Option Plan 2020 and Viyash Scientific Limited Employee Stock Option Scheme 2026.
Viyash Scientific Limited
Viyash Scientific Limited has announced its Q1 FY'27 earnings, with revenue from operations growing 20% year-on-year to Rs. 946 crores, EBITDA increasing 59% to Rs. 205 crores, and profit after tax more than doubling to Rs. 79 crores. The company's balance sheet has improved, with net debt decreasing to Rs. 86 crores and net debt to EBITDA ratio reducing to 0.1x.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about the link of earnings call recording for the unaudited financial results (consolidated and standalone) for the quarter ended June 30, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has published a copy of newspaper publication for its Q1 FY 27 financial results, as per Regulation 30 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about Investor Presentation, enclosing the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The presentation highlights the company's continued success in integration efforts, robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing the strategic focus on the companion animal segment, providing market access and a platform to launch the product portfolio in key European markets.
Viyash Scientific Limited
Viyash Scientific Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 11, 2026. The company has informed the Exchange regarding voting results for all resolutions set out in the Notice dated May 19, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has announced its Q1 FY 2026-27 financial results, with revenues up 19.5% to ₹ 9,464 million, EBITDA up 59.2% to ₹ 2,047 million, and PAT up 114.9% to ₹ 793 million.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about General Updates Allotment of ESOP under Viyash Scientific Limited -Employee Stock Option Scheme 2026. The company has also approved the incorporation of a wholly owned subsidiary in Vietnam and investment therein, and subscription of equity shares in Alivira Animal Health Limited through Rights Issue.
Viyash Scientific Limited
Viyash Scientific Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with an independent auditor's limited review report. The company has also approved the allotment of equity shares to employees under the Viyash Scientific Limited Employee Stock Option Scheme, 2026, and the incorporation of a wholly owned subsidiary in Vietnam. Additionally, the company has approved the subscription of equity shares in Alivira Animal Health Limited, a wholly owned subsidiary, through a rights issue.
Viyash Scientific Limited
Viyash Scientific Limited has scheduled a conference call with its Analysts/Investors on August 12, 2026, to discuss its Q1FY27 earnings/financial results.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about ESOP Allotment. The company has approved the allotment of 20,01,336 Equity Shares of Rs. 2/- each to eligible optionees at an exercise price of Rs. 86/- per equity share. The issued and paid-up equity share capital of the Company will increase from Rs. 87,37,50,954/- to Rs. 87,77,53,626 /-.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about General Updates - Intimation under Regulation 30 of SEBILODR regarding the execution of the Sale and Purchase Agreement for the acquisition of BioForLife Italia s.r.l. for approximately EUR 16.976 million.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 41st Annual General Meeting scheduled to be held on August 11, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about a letter to shareholders regarding the web-link of the Annual Report 2025-26 and the 41st Annual General Meeting (AGM) scheduled to be held on August 11, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has submitted its Business Responsibility and Sustainability Report for the Financial Year 2025-26, as required by SEBI regulations.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2026. The meeting will be held through video conferencing and will consider and adopt the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The re-appointment of Dr. Haribabu Bodepudi as Managing Director and Group CEO will also be considered.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about a copy of newspaper publication regarding the Forty-first Annual General Meeting scheduled to be held on August 11, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has received an administrative warning letter from SEBI regarding the maintenance of Structured Digital Database (SDD) for the period June 26, 2024, to October 18, 2024, under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Viyash Scientific Limited
Viyash Scientific Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized or rematerialized during the quarter ended June 30, 2026.